Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT05817175

International Prospective REgistry on Pre-pectorAl Breast REconstruction

International Prospective REgistry on Pre-pectorAl Breast REconstruction — Recruiting • Oncology • NCT05817175.

📅 11 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05817175
Sponsor
European Breast Cancer Research Association of Surgical Trialists
Start
2023-09-12
ClinicaliQ Trial Snapshot
  • International Prospective REgistry on Pre-pectorAl Breast REconstruction — Recruiting • Oncology • NCT05817175.
  • What is being tested: Surgical outcomes, aesthetic results, and oncological safety of pre-pectoral breast implant reconstruction following mastectomy for breast cancer across multiple international centres.
  • Patient eligibility overview: Women undergoing mastectomy for breast cancer who are candidates for pre-pectoral implant-based breast reconstruction, assessed across diverse healthcare settings globally.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is an international multicenter prospective cohort study aimed at collecting data on breast reconstruction techniques with pre-pectoral implants after mastectomy for breast cancer. The aim of the study is to collect data on the surgical, aesthetic and oncological results, as well as on the quality of life of the patients who will undergo breast reconstruction with a pre-pectoral approach.

Eligibility Snapshot
  • : * Female patients older than 18 years old * Signed informed consent form * Patients undergoing mono or bilateral therapeutic mastectomy * Patients undergoing pre-pectoral implant-based breast reconstruction with implant or expander with or without mesh

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
The Irish international rugby ‘trailblazer’ and her legacy of cancer awareness
Oncology · BBC Health · 30 Sep 2026
A prominent Irish rugby player's death from breast cancer highlights the importance of raising awareness about symptoms among younger women, even in…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
New hope for breast cancer patients as life-extending drug now on NHS in England
Oncology · BBC Health · 16 Sep 2026
Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →